Schedule 13D ownership disclosure

ORIC Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 68622P109

Event date: 2025-05-29

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SR One Capital Management, LLCReported CIK 0001853723

    Shares: 4,615,384 · Class: 5.4%

  • SR One Capital Opportunities Fund I, LP

    Shares: 2,382,064 · Class: 2.8%

  • SR One Capital Opportunities Partners I, LP

    Shares: 2,382,064 · Class: 2.8%

  • AMZL, LP

    Shares: 1,538,461 · Class: 1.8%

  • SR One Capital SMA Partners, LP

    Shares: 1,538,461 · Class: 1.8%

  • SR One Capital Fund II Aggregator, LP

    Shares: 694,859 · Class: 0.8%

  • SR One Capital Partners II, LP

    Shares: 694,859 · Class: 0.8%

  • Simeon George

    Shares: 4,615,384 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-082520
Form type
SCHEDULE 13D
Filer
Oric Pharmaceuticals, Inc.
CIK
CIK 1796280
Filed
Jun 05, 2025
Reporting period
May 29, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub